CD274 and neoplasm: For instance, in the PePS2 trial [12] that was focused on pembrolizumab-treated PS 2 patients, median OS was 14.6 months (4.6–NR) for patients with PD-L1 tumor proportion score ≥50%; thus, PD-L1 tumor expression remains a major prognostic or predictive factor.